SG11201903601QA - Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease - Google Patents
Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's diseaseInfo
- Publication number
- SG11201903601QA SG11201903601QA SG11201903601QA SG11201903601QA SG11201903601QA SG 11201903601Q A SG11201903601Q A SG 11201903601QA SG 11201903601Q A SG11201903601Q A SG 11201903601QA SG 11201903601Q A SG11201903601Q A SG 11201903601QA SG 11201903601Q A SG11201903601Q A SG 11201903601QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alzheimer
- disease
- october
- protofibril antibody
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- 102000011801 Beta-secretase BACE1 Human genes 0.000 title 1
- 108050002234 Beta-secretase BACE1 Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0111010101111101111101 0 0111111111 11111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/081460 Al 03 May 2018 (03.05.2018) W I PO I PC T (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (71) Applicants: SATLIN, Andrew [US/US]; 239 Central Park International Patent Classification: (74) Agent: MACALPINE, Jill, K.; Finnegan, Henderson, C07K 14/47 (2006.01) A61K 31/404 (2006.01) Farabow, Garrett & Dunner, LLP, 901 New York Avenue, C07K 16/18 (2006.01) A61K 39/395 (2006.01) NW, Washington, DC 20001 (US). International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2017/058587 kind of national protection available): AE, AG, AL, AM, International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 26 October 2017 (26.10.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/413,961 27 October 2016 (27.10.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/415,165 31 October 2016 (31.10.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: EISAI R&D MANAGEMENT CO., LTD. (84) Designated States (unless otherwise indicated, for every [JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo, kind of regional protection available): ARIPO (BW, GH, 112-8088 (JP). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, West #5C, New York, NY 10024 (US). FUKUSHIMA, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 5M, Tatsuto [JP/JP]; 1-3, Tokodai 5-chome, Tsukuba-shi, Ibara-TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ki, 300 2635 (JP). KM, ML, MR, NE, SN, TD, TG). — = = (54) Title: COMPOSITION FOR THE TREATMENT 0.25 - 0.20 - m 17'' 0 1 0 - 0 05 0 00 = INHIBITOR COMPRISING SOLUBLE OF AN Ar342 ALZHEIMER'S ANTI-ABETA PROTOFIBRIL ANTIBODY AND A BETA-SECRETASE DISEASE 300- 200- INSOLUBLE A1342 # BACE1 _ = = = A 0.15 = a 0 0 0 y # - • = . . A = _= : Methods disease ,1 Alzheimer's 0 methyl-4a,5,7,7a- \" pharmaceutically 7 1 1 er (S . S)N . 4 \ IZ.;) AN‘ oqb S L 4 C . ) p i p\ 4' .R 1' i ' 6) $ GO * * (# 6 ) J C) • 6 ) -i - 1 development of amino-5- and/or a 11 © oc © --- -- GC (57) tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-y1)-4- acceptable salt thereof (Compound X) are provided. Tg257.6 HETERO Tg2576 HETERO FIG. and combination therapies for treating, preventing, and/or delaying the onset and/or using an anti-A13 protofibril antibody (such as, for example, BAN2401 ) and N-[3-((4aS,5R,7aS)-2- fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide [Continued on next page] WO 2018/081460 Al MIDEDIMOMMIDEFIEHMOIDIEINIMOVOIS Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413961P | 2016-10-27 | 2016-10-27 | |
| US201662415165P | 2016-10-31 | 2016-10-31 | |
| PCT/US2017/058587 WO2018081460A1 (en) | 2016-10-27 | 2017-10-26 | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903601QA true SG11201903601QA (en) | 2019-05-30 |
Family
ID=60327389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913049QA SG10201913049QA (en) | 2016-10-27 | 2017-10-26 | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
| SG11201903601QA SG11201903601QA (en) | 2016-10-27 | 2017-10-26 | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913049QA SG10201913049QA (en) | 2016-10-27 | 2017-10-26 | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200299411A9 (en) |
| EP (1) | EP3532485A1 (en) |
| JP (3) | JP7116725B2 (en) |
| KR (2) | KR20240015733A (en) |
| CN (2) | CN117244056A (en) |
| AU (2) | AU2017347838B2 (en) |
| BR (1) | BR112019008359A2 (en) |
| CA (1) | CA3042020A1 (en) |
| IL (1) | IL266114A (en) |
| MX (1) | MX2019004872A (en) |
| SG (2) | SG10201913049QA (en) |
| WO (1) | WO2018081460A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117244056A (en) * | 2016-10-27 | 2023-12-19 | 卫材研究发展管理有限公司 | Compositions comprising anti-Abeta-protofibril antibodies and beta-secretase BACE1 inhibitors for the treatment of Alzheimer's disease |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| EP4185612A1 (en) | 2020-07-23 | 2023-05-31 | Othair Prothena Limited | Anti-abeta antibodies |
| AU2022338055A1 (en) * | 2021-08-30 | 2024-02-29 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO347079B1 (en) | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Improved protofibril-selective antibodies and use thereof |
| PE20091438A1 (en) * | 2008-01-18 | 2009-09-26 | Eisai Randd Man Co Ltd | FUSED DERIVATIVES OF AMINODIHYDROTIAZINE |
| JP5993875B2 (en) * | 2011-01-21 | 2016-09-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods and compounds useful for the synthesis of fused aminodihydrothiazine derivatives |
| EP4272763A3 (en) * | 2013-09-11 | 2024-02-14 | Eagle Biologics, Inc. | Liquid protein formulations containing organophosphates |
| US20150320706A1 (en) * | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| DK3166970T3 (en) * | 2014-07-10 | 2021-05-25 | Bioarctic Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2015329027B2 (en) | 2014-10-10 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition of fused aminodihydrothiazine derivative |
| MA41115A (en) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
| CN117244056A (en) | 2016-10-27 | 2023-12-19 | 卫材研究发展管理有限公司 | Compositions comprising anti-Abeta-protofibril antibodies and beta-secretase BACE1 inhibitors for the treatment of Alzheimer's disease |
-
2017
- 2017-10-26 CN CN202311092702.2A patent/CN117244056A/en active Pending
- 2017-10-26 SG SG10201913049QA patent/SG10201913049QA/en unknown
- 2017-10-26 KR KR1020247002649A patent/KR20240015733A/en active Search and Examination
- 2017-10-26 CA CA3042020A patent/CA3042020A1/en active Pending
- 2017-10-26 SG SG11201903601QA patent/SG11201903601QA/en unknown
- 2017-10-26 WO PCT/US2017/058587 patent/WO2018081460A1/en unknown
- 2017-10-26 KR KR1020197014830A patent/KR102630042B1/en active IP Right Grant
- 2017-10-26 EP EP17798044.8A patent/EP3532485A1/en active Pending
- 2017-10-26 AU AU2017347838A patent/AU2017347838B2/en active Active
- 2017-10-26 US US16/345,012 patent/US20200299411A9/en not_active Abandoned
- 2017-10-26 CN CN201780067181.1A patent/CN110214146B/en active Active
- 2017-10-26 BR BR112019008359A patent/BR112019008359A2/en unknown
- 2017-10-26 JP JP2019521660A patent/JP7116725B2/en active Active
- 2017-10-26 MX MX2019004872A patent/MX2019004872A/en unknown
-
2019
- 2019-04-17 IL IL266114A patent/IL266114A/en unknown
-
2022
- 2022-04-11 JP JP2022065210A patent/JP7319421B2/en active Active
- 2022-07-05 US US17/857,931 patent/US20230146896A1/en active Pending
-
2023
- 2023-07-20 JP JP2023118093A patent/JP2023139116A/en active Pending
- 2023-07-25 AU AU2023208107A patent/AU2023208107A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017347838B2 (en) | 2023-04-27 |
| KR20240015733A (en) | 2024-02-05 |
| CN117244056A (en) | 2023-12-19 |
| SG10201913049QA (en) | 2020-02-27 |
| JP2023139116A (en) | 2023-10-03 |
| WO2018081460A1 (en) | 2018-05-03 |
| CA3042020A1 (en) | 2018-05-03 |
| AU2017347838A1 (en) | 2019-06-13 |
| EP3532485A1 (en) | 2019-09-04 |
| US20200299411A9 (en) | 2020-09-24 |
| JP2022092013A (en) | 2022-06-21 |
| JP2020500165A (en) | 2020-01-09 |
| JP7319421B2 (en) | 2023-08-01 |
| MX2019004872A (en) | 2019-10-30 |
| US20230146896A1 (en) | 2023-05-11 |
| AU2023208107A1 (en) | 2023-08-17 |
| CN110214146A (en) | 2019-09-06 |
| US20190276560A1 (en) | 2019-09-12 |
| RU2019116018A3 (en) | 2021-02-05 |
| KR102630042B1 (en) | 2024-01-29 |
| CN110214146B (en) | 2023-08-29 |
| IL266114A (en) | 2019-06-30 |
| BR112019008359A2 (en) | 2019-10-01 |
| KR20190102181A (en) | 2019-09-03 |
| JP7116725B2 (en) | 2022-08-10 |
| RU2019116018A (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201903601QA (en) | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201809527UA (en) | Methods of treating circadian rhythm sleep disorders | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201901271VA (en) | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201810333UA (en) | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders |